List of Excipients in Branded Drug AKEEGA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Janssen Biotech Inc	AKEEGA	niraparib tosylate monohydrate and abiraterone acetate	57894-100	CELLULOSE, MICROCRYSTALLINE	2031-03-27
Janssen Biotech Inc	AKEEGA	niraparib tosylate monohydrate and abiraterone acetate	57894-100	CROSPOVIDONE	2031-03-27
Janssen Biotech Inc	AKEEGA	niraparib tosylate monohydrate and abiraterone acetate	57894-100	FERRIC OXIDE RED	2031-03-27
Janssen Biotech Inc	AKEEGA	niraparib tosylate monohydrate and abiraterone acetate	57894-100	FERRIC OXIDE YELLOW	2031-03-27

AKEEGA Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Akeega is a fixed-dose oral combination of niraparib and abiraterone acetate for adults with BRCA-mutated metastatic castration-resistant prostate cancer, administered with prednisone or prednisolone. Its excipient strategy is constrained by abiraterone acetate’s pronounced food effect, the high drug load, once-daily dosing, and the need to preserve dissolution performance across two strengths. The strongest commercial opportunities are in qualified excipient substitution, particle engineering, direct-compression platforms, coating systems, and generic development support rather than in novel excipients alone.

What is Akeega and how is it administered?

Akeega combines a PARP inhibitor with an androgen-biosynthesis inhibitor in a single tablet.

Parameter	Akeega details
Active ingredients	Niraparib as niraparib tosylate and abiraterone acetate
Approved strengths	50 mg niraparib/500 mg abiraterone acetate; 100 mg niraparib/500 mg abiraterone acetate
Standard adult dose	200 mg niraparib and 1,000 mg abiraterone acetate once daily
Tablets per dose	Two tablets once daily
Combination therapy	Prednisone or prednisolone
Therapeutic area	Metastatic castration-resistant prostate cancer
FDA approval	June 2023
Sponsor	Janssen Biotech, Inc., part of Johnson & Johnson
Regulatory pathway	New drug application
Biologic status	Not a biologic; biosimilar pathway is not applicable

The product must be taken on an empty stomach. Patients should take Akeega at least one hour before or two hours after food. This requirement reflects abiraterone acetate exposure, which increases materially with food and can create clinically relevant variability.[1]

The two-tablet daily dose also creates an opportunity for dose simplification, but the high abiraterone load limits how small the dosage form can become.

What excipients are used in Akeega tablets?

Akeega’s US labeling identifies conventional oral solid-dose excipients. The formulation uses a high-drug-load tablet platform with disintegrants, flow aids, lubricants, surfactant functionality, and a film coating.[1]

The principal inactive ingredients identified in labeling include:

Excipient class	Reported or functionally relevant excipients	Primary role
Diluent and compression aid	Lactose monohydrate; microcrystalline cellulose	Tablet mass, compactability, mechanical strength
Disintegrant	Croscarmellose sodium	Tablet breakup and drug release
Surfactant or wetting aid	Sodium lauryl sulfate	Wetting and dissolution support
Glidant	Colloidal silicon dioxide	Powder flow and content uniformity
Lubricant	Magnesium stearate	Ejection and tooling protection
Film-coating system	Hypromellose or equivalent polymer system, titanium dioxide, talc, iron oxide pigments	Protection, identification, swallowability, appearance

Exact excipient composition can differ by market, strength, and regulatory presentation. US and non-US product information should be assessed separately before using an Akeega composition as a reference formulation.

The formulation is commercially important because it uses familiar excipients that are broadly available from multiple suppliers. That reduces supply-chain concentration risk but raises the importance of process control, particle-size matching, grade selection, and dissolution equivalence.

Why is abiraterone the main excipient challenge?

Abiraterone acetate has low aqueous solubility and a clinically significant food effect. The formulation must support drug release without creating an unintended food-like increase in exposure.

The main technical risks are:

1. Excessive surfactant activity that accelerates or changes abiraterone dissolution.
2. Over-lubrication, particularly with magnesium stearate, which can slow dissolution.
3. Segregation between the high-dose abiraterone fraction and the lower-dose niraparib fraction.
4. Moisture-driven changes in granule properties, tablet hardness, or dissolution.
5. Compression conditions that produce a dense tablet with delayed disintegration.
6. Excipient interactions that alter the relative release of the two active ingredients.

A formulation optimized only for rapid dissolution may not be commercially optimal. The target is reproducible release that remains consistent with the clinical food restriction and the approved product profile.

What excipient strategy best supports Akeega development?

A practical Akeega formulation strategy has five components.

1. Use a robust high-load tablet platform

The 500 mg abiraterone acetate load dominates the tablet. Microcrystalline cellulose and lactose provide a conventional compression base, while croscarmellose sodium offsets the risk of slow tablet breakup caused by high compaction force.

Direct compression is attractive because it reduces unit operations and avoids wetting a compound whose stability and particle properties may be sensitive to moisture. Roller compaction can be considered where flow or compressibility is inadequate, but it introduces additional controls for ribbon density, granule size, and dissolution.

2. Control surfactant concentration

Sodium lauryl sulfate can improve wetting of poorly soluble abiraterone acetate. Its level should be controlled tightly because small changes can affect dissolution, impurity formation, and the relationship between in vitro and in vivo performance.

Potential alternatives include poloxamers, sodium docusate, or other wetting systems. These alternatives may offer commercial differentiation, but they also create regulatory comparability work and may change the food-effect profile. A substitution is therefore more defensible when it solves a measurable problem such as dissolution variability, sticking, or supplier continuity.

3. Protect content uniformity

The two active ingredients have different dose levels and physicochemical properties. Niraparib represents a smaller portion of tablet mass than abiraterone acetate, creating a segregation risk during blending, transfer, and compression.

Commercially relevant controls include:

• Narrow particle-size distributions for both active ingredients.
• Matching bulk density where possible.
• Ordered mixing or engineered agglomeration.
• Low-shear transfer after final blending.
• In-process blend uniformity and tablet assay controls.
• Separate evaluation of niraparib and abiraterone dissolution.

A co-processed excipient could improve flow and reduce segregation, but it would need to demonstrate compatibility with the approved dissolution profile and manufacturing process.

4. Optimize lubrication and disintegration together

Magnesium stearate is commercially attractive because it is inexpensive, widely qualified, and available from multiple suppliers. Its principal risk is excessive hydrophobic coating of particles, particularly when blending time or lubricant concentration is high.

Potential strategies include:

• Lowering lubricant exposure while maintaining ejection performance.
• Using a controlled-particle-size magnesium stearate grade.
• Evaluating sodium stearyl fumarate where dissolution is more sensitive to magnesium stearate.
• Increasing disintegrant efficiency rather than simply increasing disintegrant concentration.
• Using tablet porosity and compression force as primary release controls.

A lubricant change can affect hardness, friability, ejection force, dissolution, and scale-up behavior. It is a formulation change, not merely a procurement change.

5. Use the film coat for identification and process protection

The coating system can support strength differentiation, improve swallowability, reduce dusting, and provide light or moisture protection. It is unlikely to be the primary source of product differentiation, but it can support supply-chain flexibility.

Commercial opportunities include:

• Ready-to-use coating systems with equivalent pigments.
• Lower-temperature coating processes for improved stability.
• Reduced coating weight to increase throughput.
• Alternative polymer systems with comparable appearance and protection.
• Pigment systems that simplify global colorant compliance.

The coating must not materially delay disintegration or alter dissolution.

What formulation patents protect Akeega?

Akeega’s core product is likely protected through a combination of drug-substance, combination-product, formulation, manufacturing, and method-of-use rights. The relevant patent categories are:

Patent category	Relevance to Akeega
Niraparib composition patents	Protect the PARP inhibitor active ingredient and related salts
Abiraterone acetate patents	Cover the androgen-biosynthesis inhibitor and its formulations
Fixed-dose combination patents	Potentially cover co-formulation of niraparib and abiraterone
Dosage-regimen patents	May cover once-daily dosing or use in biomarker-defined prostate cancer
Formulation patents	May cover excipient combinations, particle sizes, dissolution, or tablet architecture
Manufacturing patents	May cover granulation, blending, compression, or coating processes
Method-of-use patents	May cover BRCA-mutated mCRPC or combination treatment with prednisone

A generic manufacturer cannot assume that using different excipients avoids infringement. A non-infringing product may still face method-of-use, dosage-regimen, formulation, or manufacturing claims.

The Orange Book should be reviewed for the specific Akeega NDA and listed patents, while broader freedom-to-operate work should include the underlying niraparib and abiraterone estates. Orange Book status can change through patent-listing updates, delistings, pediatric extensions, and litigation outcomes.[2]

When does Akeega lose exclusivity?

Akeega’s commercial exclusivity has several layers:

1. FDA regulatory exclusivity for the new combination.
2. Patent protection covering Akeega or its components.
3. Patent protection for the approved method of use.
4. Patent protection for formulations and manufacturing processes.
5. Market and commercial barriers created by the complexity of reproducing the product.

The FDA approved Akeega in 2023 under an NDA. The applicable new-drug exclusivity period is distinct from patent expiration and does not itself determine the earliest commercial generic launch date.[2]

The key commercial dates are therefore patent-specific. A single expiration date cannot reliably describe Akeega’s full protection because different patents can expire at different times and may include patent-term adjustment or pediatric exclusivity.

What generic entry risks exist for Akeega?

The primary threat is an Abbreviated New Drug Application for the combination tablet. A generic applicant could seek approval through a 505(j) pathway if it can establish pharmaceutical equivalence, bioequivalence, and compliance with applicable patent certifications.[3]

The main generic risks are:

• Paragraph IV challenges to listed patents.
• Paragraph III certifications for patents that remain valid but are not challenged.
• Carve-outs for protected method-of-use indications.
• Delayed entry caused by 30-month litigation stays.
• Difficulty reproducing dissolution for poorly soluble abiraterone acetate.
• Difficulty matching the approved fasting administration profile.
• Manufacturing complexity from the high abiraterone load and lower niraparib dose.
• Need to manage separate strengths and tablet-identification requirements.

The most credible generic strategy is likely to use the same broad excipient classes while optimizing grade, particle size, and process parameters to achieve bioequivalence. A substantially different formulation could increase regulatory and clinical risk.

Which companies are positioned to challenge Akeega?

Potential challengers include large generic manufacturers with experience in complex oral solids, oncology products, and Paragraph IV litigation. Likely capabilities include:

• Bioequivalence development for poorly soluble drugs.
• High-dose direct compression.
• Multi-strength product manufacture.
• Global regulatory filings.
• Patent litigation financing and settlement negotiation.
• Commercial access to oncology distribution channels.

No biosimilar competitor is relevant because Akeega is a small-molecule tablet, not a biologic. The relevant competitive set consists of generic Akeega, separate niraparib and abiraterone regimens, and alternative PARP inhibitor or androgen-receptor pathway products.

How does Akeega compare with separate niraparib and abiraterone therapy?

Attribute	Akeega	Separate products
Administration	Two fixed-dose tablets once daily, plus prednisone or prednisolone	Separate product dosing and adherence requirements
Excipient control	Single combined formulation	Independent formulations
Food restriction	Must follow abiraterone fasting instructions	Abiraterone still requires fasting; niraparib may have different administration flexibility
Manufacturing	High-dose combination tablet with two actives	Simpler single-active manufacturing
Generic complexity	Higher due to fixed-dose combination and comparative dissolution	Potentially lower for each single-active product
Commercial value	Convenience and regimen integration	Greater prescribing and formulation flexibility
Substitution risk	Generic fixed-dose combination and component-level substitution	Component products may compete separately

Akeega’s value proposition depends partly on reducing pill burden and integrating treatment. Excipient changes that increase tablet size, cause swallowing problems, or create visible differences between strengths could weaken that advantage.

What commercial opportunities exist for excipient suppliers?

The best opportunities are functional and supply-chain driven.

Qualified alternative excipients

Suppliers can position equivalent grades of microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, and coating polymers. The opportunity is strongest where the supplier can provide:

• Consistent particle-size distribution.
• Low and controlled moisture.
• Reliable bulk density.
• Documentation for global regulatory filings.
• Multiple manufacturing sites.
• Pharmaceutical-grade change-control support.

Co-processed excipients

Co-processed systems could improve flow, compressibility, and content uniformity. They are most attractive if they reduce compression force or prevent segregation without increasing tablet size.

The commercial barrier is regulatory comparability. A co-processed excipient is more difficult to replace late in development than a conventional single-component excipient.

Surfactant and dissolution platforms

Formulation developers may seek improved wetting systems for abiraterone acetate. Suppliers with data on dissolution, supersaturation control, and food-effect risk have a stronger position than suppliers offering a surfactant solely on price.

Particle engineering

Micronized or engineered abiraterone acetate may reduce dependence on high surfactant levels and improve dissolution consistency. The opportunity includes spray-dried dispersions, nanocrystalline systems, and surface-modified particles, although these approaches can increase manufacturing and regulatory complexity.

Film-coating systems

Ready-to-use coatings can support strength differentiation, reduce development time, and simplify global scale-up. The opportunity is commercially smaller than the core-tablet opportunity but can generate recurring supply revenue.

What manufacturing and IP barriers affect excipient commercialization?

Excipient suppliers face four practical barriers.

First, formulation know-how may be protected even when the excipients themselves are not. The combination of excipient type, concentration, particle size, and process conditions can support formulation patent claims.

Second, a supplier change can trigger comparability studies, stability work, dissolution testing, and regulatory notifications.

Third, supplier qualification requires more than pharmacopoeial compliance. Batch-to-batch variability in density, moisture, surface area, or lubrication behavior can affect tablet performance.

Fourth, a supplier must support commercial continuity. Dual sourcing is attractive, but alternative grades must be available before a supply disruption occurs, not after a product launch.

What is the FDA regulatory status of Akeega?

The FDA approved Akeega in June 2023 for adults with deleterious or suspected deleterious BRCA mutations in the treatment of mCRPC, in combination with prednisone.[4] The product is a prescription oral tablet and is not subject to biosimilar competition.

A generic applicant would generally need to demonstrate equivalence to the reference listed drug, including strength, dosage form, route of administration, quality attributes, and bioequivalence. For this combination, comparative dissolution and the treatment of abiraterone’s food effect are central development issues.[3]

Key Takeaways

• Akeega is a high-drug-load, fixed-dose tablet containing niraparib and abiraterone acetate.
• Abiraterone acetate drives the main excipient and dissolution constraints.
• The most commercially useful excipient opportunities are qualified substitutions, co-processed systems, surfactant platforms, particle engineering, and coating systems.
• Magnesium stearate, sodium lauryl sulfate, disintegrant performance, and powder segregation require tight process control.
• Akeega has generic rather than biosimilar risk.
• Patent analysis must cover the combination product, niraparib, abiraterone acetate, formulation, manufacturing, and method-of-use claims.
• Generic entry will depend on patent certifications, potential Paragraph IV litigation, bioequivalence, and replication of the fasting administration profile.
• Excipient suppliers with global regulatory documentation and dual-site manufacturing have the strongest commercial positioning.

FAQs

Can Akeega use a different lubricant from magnesium stearate?

Yes. Sodium stearyl fumarate and other lubricants may be technically viable, but the change requires evaluation of ejection force, tablet strength, disintegration, dissolution, stability, and bioequivalence impact.

Is sodium lauryl sulfate essential to Akeega?

It is not inherently essential, but a wetting aid may be important because abiraterone acetate is poorly soluble. Removing or replacing it could materially change dissolution and exposure.

Can a generic manufacturer make Akeega with separate tablets?

A separate-tablet product would not be the same fixed-dose combination product. It may compete commercially, but it would face different regulatory, labeling, patent, and substitution requirements.

Does Akeega have biosimilar competition?

No. Akeega is a small-molecule oral tablet. Competition would arise from generic fixed-dose combinations, separate niraparib and abiraterone products, and other prostate-cancer therapies.

Which excipient property is most important for Akeega scale-up?

Consistent powder flow and bulk-density control are among the most important properties because the product combines a high-dose active ingredient with a lower-dose active ingredient in a compressed tablet.

References

1. DailyMed. (2024). Akeega: Niraparib and abiraterone acetate tablet, film coated, prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2017). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA.

4. U.S. Food and Drug Administration. (2023, June 20). FDA approves niraparib and abiraterone acetate plus prednisone for BRCA-mutated metastatic castration-resistant prostate cancer. FDA.